Top Wall Street Analysts Upgrade Stocks for Monday

Several analysts have upgraded their ratings for various stocks. Wolfe Research upgraded Alnylam Pharmaceuticals from Underperform to Peer Perform, while Baird upgraded Alamo Group from Neutral to Outperform. Telsey Advisory Group upgraded Zevia from Market Perform to Outperform, and Wolfe Research upgraded Apartment Investment and Management Company from Peer Perform to Outperform. These upgrades reflect positive sentiment from analysts on these companies' future prospects.

Several analysts have recently upgraded their ratings for various stocks, reflecting positive sentiment about the future prospects of these companies. Wolfe Research upgraded Alnylam Pharmaceuticals from Underperform to Peer Perform, while Baird upgraded Alamo Group from Neutral to Outperform. Telsey Advisory Group upgraded Zevia from Market Perform to Outperform, and Wolfe Research upgraded Apartment Investment and Management Company from Peer Perform to Outperform.

Wolfe Research, in particular, highlighted Alnylam Pharmaceuticals' (NASDAQ:ALNY) improved patient acquisition capabilities, which led to the stock's upgrade. The company has shown remarkable momentum, surging 23.71% in the past week and currently trading near its 52-week high at $419.66. Despite valuation concerns, Wolfe Research believes the stock is more likely to trade upward in the near term [1].

Baird analyst Mig Dobre upgraded Alamo Group (NYSE:ALG) to Outperform from Neutral, citing early signs of stabilization in key end markets and meaningful earnings growth potential into 2026. The company's vegetation and industrial segments are showing positive momentum, with improving conditions in hay and alfalfa prices, a slowdown in dealer destocking, and improving retail demand for small tractors supporting the firm's view that Alamo is well-positioned for gains [2].

Telsey Advisory Group analyst Dana Telsey upgraded Zevia PBC (ZVIA) from Market Perform to Outperform, raising the price target from $3 to $5. This upgrade reflects positive expectations for the company's future performance [3].

These upgrades come as a boost for investors, signaling confidence in the companies' ability to deliver strong financial results and growth in the near term. However, it is essential for investors to conduct thorough due diligence and consider their individual investment goals and risk tolerance before making any investment decisions.

References:
[1] https://www.investing.com/news/analyst-ratings/wolfe-research-upgrades-alnylam-pharmaceuticals-stock-rating-to-peerperform-93CH-4168501
[2] https://seekingalpha.com/news/4477407-alamo-group-upgraded-at-baird-on-signs-of-recovery-earnings-power
[3] https://www.marketscreener.com/news/telsey-advisory-upgrades-zevia-pbc-to-outperform-from-market-perform-hikes-price-target-to-5-from-ce7c5edadc88f22c